Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases

@inproceedings{Albach2017SafetyPA,
  title={Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases},
  author={Fredrik N. Albach and Frank D Wagner and Andreas H{\"u}ser and Julia Igel and David O Joseph and James Hilbert and Corinna Schoelch and Steven J. Padula and Juergen Steffgen},
  booktitle={European Journal of Clinical Pharmacology},
  year={2017}
}
The CD40–CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis. The safety, pharmacokinetics and pharmacodynamics of BI 655064, a novel humanised antagonistic anti-CD40 monoclonal antibody, were investigated in this first-in-human trial. Healthy male subjects (n = 72) were randomised 3:1, within each BI 655064 dose group, to single intravenous (IV; 0.2–120 mg) or subcutaneous (SC; 40–120 mg) doses of… CONTINUE READING
1 Extracted Citations
37 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 37 references

guideline for good clinical practice

  • International Conference on Harmonisation of technical requireme guideline
  • J Postgrad Med 47(1):45–50 Eur J Clin Pharmacol
  • 2018
1 Excerpt

Preclinical characterization of a highly selective and potent antagonistic anti-CD40 mAb

  • K Ralph, A Nicoletti, +19 authors C Grimaldi
  • Ann Rheum Dis 74(Suppl2):344
  • 2015
2 Excerpts

erythematosus

  • R Goldwater, J Keirns, +5 authors J Holman
  • 2013

Similar Papers

Loading similar papers…